97.93
-0.07 (-0.07%)
| Penutupan Terdahulu | 98.00 |
| Buka | 99.06 |
| Jumlah Dagangan | 752,440 |
| Purata Dagangan (3B) | 524,898 |
| Modal Pasaran | 7,698,962,944 |
| Harga / Buku (P/B) | 6.31 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| EPS Cair (TTM) | -4.42 |
| Nisbah Semasa (MRQ) | 14.48 |
| Aliran Tunai Operasi (OCF TTM) | -203.80 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -98.58 M |
| Pulangan Atas Aset (ROA TTM) | -22.23% |
| Pulangan Atas Ekuiti (ROE TTM) | -35.69% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Nuvalent, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | 0.60 |
|
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company’s operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.85% |
| % Dimiliki oleh Institusi | 110.02% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 145.00 (JP Morgan, 48.07%) | Beli |
| Median | 142.50 (45.51%) | |
| Rendah | 140.00 (Cantor Fitzgerald, 42.96%) | Beli |
| Purata | 142.50 (45.51%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 102.88 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 27 Feb 2026 | 140.00 (42.96%) | Beli | 101.95 |
| JP Morgan | 19 Dec 2025 | 145.00 (48.06%) | Beli | 103.80 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| PORTER JAMES RICHARD | - | 99.41 | -30,000 | -2,982,300 |
| Jumlah Keseluruhan Kuantiti Bersih | -30,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -2,982,300 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 99.41 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PORTER JAMES RICHARD | Pegawai | 06 Mar 2026 | Jual automatik (-) | 30,000 | 99.41 | 2,982,300 |
| PORTER JAMES RICHARD | Pegawai | 06 Mar 2026 | Pelaksanaan pilihan | 30,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 |
| 12 Jan 2026 | Pengumuman | Nuvalent Announces OnTarget 2026 Operating Plan Progress and Outlines Key Anticipated 2026 Milestones |
| 22 Dec 2025 | Pengumuman | Nuvalent to Present at the 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |